Unique ID issued by UMIN | UMIN000013019 |
---|---|
Receipt number | R000015187 |
Scientific Title | Phase 2 study of alternate-day administrations of S-1 in elderly patients with advanced/recurrent gastric cancer (KDOG 1301) |
Date of disclosure of the study information | 2014/01/30 |
Last modified on | 2020/08/05 13:54:12 |
Phase 2 study of alternate-day administrations of S-1 in elderly patients with advanced/recurrent gastric cancer (KDOG 1301)
Phase 2 study of alternate-day administrations of S-1 in elderly patients with gastric cancer (KDOG 1301)
Phase 2 study of alternate-day administrations of S-1 in elderly patients with advanced/recurrent gastric cancer (KDOG 1301)
Phase 2 study of alternate-day administrations of S-1 in elderly patients with gastric cancer (KDOG 1301)
Japan |
Advanced or recurrent gastric cancer
Gastroenterology |
Malignancy
NO
efficacy
Safety
Phase II
response rate
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
S-1
76 | years-old | <= |
Not applicable |
Male and Female
1. Unresectable advanced or recurrent gastric carcinoma which was confirmed histologically
2. negative or non-measurement of HER2
3. Patient with the measurable lesion
4. 76 years or older
5. ECOG performance status: 0-2
6. Chemo-naive patient
7. Sufficient organ functions in laboratory data within 14 days before enrollment
8. Possible of oral ingestion
9. Written informed consent
1. History of hypersensitivity for S-1 or ingredients of S-1
2. Patient who takes flucytosine, or phenytoin
3. Severe bone marrow suppression, severe renal dysfunction, or severe liver dysfunction
4. Severe concomitant disease (congestive heart failure, hemorrhagic peptic ulcer, ileus, symptomatic ischemic heart disease, liver cirrhosis, interstitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema or etc)
5. Patient who suffered from myocardial infarction or cerebral infarction within six months
6. symptomatic brain metastasis
7. Severe mental disorders
8. Active synchronous malignancy
9. Watery diarrhea
10. HBV carrier who has to take nucleotide analogues (e.g. Entecavir) during chemotherapy
11. Patient who is judged inappropriate for the entry into this study by the investigator
45
1st name | Wasaburo |
Middle name | |
Last name | Koizumi |
Kitasato University School of Medicine
Department of Gastroenterology
2520374
1-15-1, Kitazato, Minami-ku, Sagamihara, Kanagawa, 252-0380 Japan
042-778-8111
koizumi@med.kitasato-u.ac.jp
1st name | Kenji |
Middle name | |
Last name | Ishido |
Kitasato University School of Medicine
Department of Gastroenterology
252-0374
1-15-1, Kitazato, Minami-ku, Sagamihara, Kanagawa, 252-0380 Japan
042-778-8111
k.ishido@kitasato-u.ac.jp
Department of Gastroenterology, Kitasato University School of Medicine
Department of Gastroenterology, Kitasato University School of Medicine
Self funding
Kitasato University School of Medicine Hospital Ethic Comittee
1-15-1, Kitazato, Minami-ku, Sagamihara, Kanagawa, 252-0380 Japan
042-778-9111
rinrib@med.kitasato-u.ac.jp
NO
2014 | Year | 01 | Month | 30 | Day |
none
Published
clinical trial discontinued
6
Clinical trial discontinued due to sluggish accumulation of 6 registered cases
2020 | Year | 08 | Month | 05 | Day |
Clinical trial discontinued due to sluggish accumulation of 6 registered cases
Clinical trial discontinued due to sluggish accumulation of 6 registered cases
none
Clinical trial discontinued due to sluggish accumulation of 6 registered cases
Completed
2014 | Year | 01 | Month | 21 | Day |
2014 | Year | 01 | Month | 21 | Day |
2014 | Year | 01 | Month | 30 | Day |
2018 | Year | 01 | Month | 30 | Day |
2018 | Year | 01 | Month | 30 | Day |
2018 | Year | 01 | Month | 30 | Day |
2018 | Year | 01 | Month | 30 | Day |
2014 | Year | 01 | Month | 30 | Day |
2020 | Year | 08 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015187